Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Cardiovascular Diabetology|November 29, 2023
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trialAkihiko Koshino, Brendon L Neuen, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2021
Urine APOL1 Isoforms Reflect Plasma-Derived Liver-Synthesized ProteinsMagnus Althage, Timothy M Heinrich, Tasso Miliotis, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 26, 2023
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trialHiddo J L Heerspink, Peter J Greasley, Christine Ahlström, et al.
Diabetes Care|December 15, 2020
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT TrialRosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, et al.
Iscience|May 30, 2023
APOL1 promotes endothelial cell activation beyond the glomerulusMiguel Carracedo, Elke Ericson, Rasmus Ågren, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 28, 2020
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitiumAnna Levin, Anna Reznichenko, Anna Witasp, et al.
Diabetes, Obesity & Metabolism|April 28, 2021
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trialsAnnemarie B van der Aart-van der Beek, David Cherney, Gozewijn D Laverman, et al.
Kidney International Reports|May 16, 2022
The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled DietRosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, et al.
JAMA Surgery|July 3, 2024
Gastric Bypass vs Diet and Cardiovascular Risk Factors: A Nonrandomized Controlled TrialCecilia Karlsson, Line Kristin Johnson, Peter J Greasley, et al.
Journal of the American Society of Nephrology : JASN|April 2, 2026
Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 InhibitionErik Moedt, Akihiko Koshino, Niels Jongs, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Cardiovascular Diabetology|November 29, 2023
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trialAkihiko Koshino, Brendon L Neuen, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2021
Urine APOL1 Isoforms Reflect Plasma-Derived Liver-Synthesized ProteinsMagnus Althage, Timothy M Heinrich, Tasso Miliotis, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 26, 2023
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trialHiddo J L Heerspink, Peter J Greasley, Christine Ahlström, et al.
Diabetes Care|December 15, 2020
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT TrialRosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, et al.
Iscience|May 30, 2023
APOL1 promotes endothelial cell activation beyond the glomerulusMiguel Carracedo, Elke Ericson, Rasmus Ågren, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 28, 2020
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitiumAnna Levin, Anna Reznichenko, Anna Witasp, et al.
Diabetes, Obesity & Metabolism|April 28, 2021
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trialsAnnemarie B van der Aart-van der Beek, David Cherney, Gozewijn D Laverman, et al.
Kidney International Reports|May 16, 2022
The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled DietRosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, et al.
JAMA Surgery|July 3, 2024
Gastric Bypass vs Diet and Cardiovascular Risk Factors: A Nonrandomized Controlled TrialCecilia Karlsson, Line Kristin Johnson, Peter J Greasley, et al.
Journal of the American Society of Nephrology : JASN|April 2, 2026
Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 InhibitionErik Moedt, Akihiko Koshino, Niels Jongs, et al.
Pageof 9